Literature DB >> 9227163

Serum immunoglobulins and the risk of rheumatoid arthritis.

K Aho1, M Heliövaara, P Knekt, A Reunanen, A Aromaa, A Leino, P Kurki, R Heikkilä, T Palosuo.   

Abstract

OBJECTIVE: Rheumatoid arthritis (RA) is associated with several autoantibodies that can precede the clinical disease. The immunoglobulin concentrations in serum samples before illness were studied to learn more about the immunological process before RA.
METHODS: A case-control study was nested within a Finnish cohort of 19,072 adults who had neither arthritis nor a history of it at the baseline examination during 1973-1977. By late 1989, 124 had developed RA, of which 89 were positive for rheumatoid factor (RF). Three controls per each incident case were individually matched for sex, age, and municipality. The concentrations of IgG, IgA, and IgM were measured from stored serum samples.
RESULTS: Serum IgG before illness was found to be directly proportional to the risk of RF positive RA, and a non-linear association was present between serum IgA and the risk of RF positive RA. These associations were constant between men and women and other subgroups of the study population and not confounded by serum orosomucoid concentration, level of education, smoking, alcohol intake or body mass index. As adjusted for these factors, the odds ratios (95% confidence intervals) of RF positive RA in the lowest, mid, and highest tertiles of IgG distribution were 1.00, 1.55 (0.81, 2.97), and 2.22 (1.16, 4.26), and in the tertiles of IgA 1.00, 2.23 (1.14, 4.36), and 1.78 (0.89, 3.57), respectively. The associations persisted throughout the entire observation period but were most distinct when the period to the onset of clinical RA was > or = 10 years. IgM carried no predictive significance. None of the serum immunoglobulins predicted the development of RF negative RA.
CONCLUSIONS: Increased IgG levels may reflect some, at present unknown process in the early events leading to the development of RA, typically occurring > or = 10 years before the onset of clinical disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9227163      PMCID: PMC1752401          DOI: 10.1136/ard.56.6.351

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  30 in total

1.  EB-virus and rheumatoid arthritis: new insights into their interrelation.

Authors:  K Aho; V Raunio
Journal:  Med Biol       Date:  1982-04

2.  Biologic variation of human serum immunoglobulin concentrations: sex-age specific effects.

Authors:  J T Cassidy; G L Nordby; H J Dodge
Journal:  J Chronic Dis       Date:  1974-12

3.  Chrysotherapy. Suppression of immunoglobulin synthesis.

Authors:  A Lorber; T Simon; J Leeb; A Peter; S Wilcox
Journal:  Arthritis Rheum       Date:  1978 Sep-Oct

4.  Lifestyle and the risk of rheumatoid arthritis: cigarette smoking and alcohol consumption.

Authors:  J M Hazes; B A Dijkmans; J P Vandenbroucke; R R de Vries; A Cats
Journal:  Ann Rheum Dis       Date:  1990-12       Impact factor: 19.103

5.  Oral contraceptives, cigarette smoking and other factors in relation to arthritis.

Authors:  M P Vessey; L Villard-Mackintosh; D Yeates
Journal:  Contraception       Date:  1987-05       Impact factor: 3.375

6.  Smoking and risk of rheumatoid arthritis.

Authors:  M Heliövaara; K Aho; A Aromaa; P Knekt; A Reunanen
Journal:  J Rheumatol       Date:  1993-11       Impact factor: 4.666

7.  Seronegative rheumatoid arthritis: a clinical study with HLA typing.

Authors:  K Kaarela; Z Alekberova; K Lehtinen; K Puolakka; S Koskimies; V Nassonova; L Pospelov
Journal:  J Rheumatol       Date:  1990-09       Impact factor: 4.666

8.  Immunoglobulin levels in rheumatoid arthritis: comparison with rheumatoid factor titers, clinical stage and disease duration.

Authors:  J Arden; F Mullinax; M Waller
Journal:  Arthritis Rheum       Date:  1967-06

9.  When does rheumatoid disease start?

Authors:  K Aho; T Palosuo; V Raunio; P Puska; A Aromaa; J T Salonen
Journal:  Arthritis Rheum       Date:  1985-05

10.  The clinical value of measuring immunoglobulins when assessing penicillamine therapy in rheumatoid arthritis.

Authors:  A Williams; D L Scott; A Greenwood; E C Huskisson
Journal:  Clin Rheumatol       Date:  1988-09       Impact factor: 2.980

View more
  16 in total

Review 1.  Gene, environment, microbiome and mucosal immune tolerance in rheumatoid arthritis.

Authors:  Anca I Catrina; Kevin D Deane; Jose U Scher
Journal:  Rheumatology (Oxford)       Date:  2014-12-23       Impact factor: 7.580

2.  Regional differences in the incidence of rheumatoid arthritis in Finland in 1995.

Authors:  O Kaipiainen-Seppänen; K Aho; M Nikkarinen
Journal:  Ann Rheum Dis       Date:  2001-02       Impact factor: 19.103

3.  The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner.

Authors:  Kevin D Deane; Colin I O'Donnell; Wolfgang Hueber; Darcy S Majka; Ann A Lazar; Lezlie A Derber; William R Gilliland; Jess D Edison; Jill M Norris; William H Robinson; V Michael Holers
Journal:  Arthritis Rheum       Date:  2010-11

Review 4.  Preclinical Rheumatoid Arthritis and Rheumatoid Arthritis Prevention.

Authors:  Kevin D Deane
Journal:  Curr Rheumatol Rep       Date:  2018-06-26       Impact factor: 4.592

Review 5.  Autoimmunity, inflammation, and dysbiosis mutually govern the transition from the preclinical to the clinical stage of rheumatoid arthritis.

Authors:  Alexander Kalinkovich; Gulzan Gabdulina; Gregory Livshits
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

6.  Elevation of serum immunoglobulin free light chains during the preclinical period of rheumatoid arthritis.

Authors:  Xiaoli Deng; Cynthia S Crowson; S Vincent Rajkumar; Angela Dispenzieri; Dirk R Larson; Terry M Therneau; Eric L Matteson; Robert A Kyle; Jerry A Katzmann; Sherine E Gabriel; John M Davis
Journal:  J Rheumatol       Date:  2015-01-15       Impact factor: 4.666

7.  Incidence of inflammatory joint diseases in Finland: results from a population-based epidemiological study.

Authors:  A Kononoff; L Arstila; P Pussinen; H Kautiainen; P Elfving; E Savolainen; H Niinisalo; J Rutanen; O Marjoniemi; O Kaipiainen-Seppänen
Journal:  Rheumatol Int       Date:  2017-08-08       Impact factor: 2.631

8.  Autoantibodies binding to citrullinated telopeptide of type II collagen and to cyclic citrullinated peptides predict synergistically the development of seropositive rheumatoid arthritis.

Authors:  Marja-Kaisa Koivula; Markku Heliövaara; Jarmo Ramberg; Paul Knekt; Harri Rissanen; Timo Palosuo; Juha Risteli
Journal:  Ann Rheum Dis       Date:  2007-05-01       Impact factor: 19.103

9.  Serum androgen-anabolic hormones and the risk of rheumatoid arthritis.

Authors:  R Heikkilä; K Aho; M Heliövaara; P Knekt; A Reunanen; A Aromaa; A Leino; T Palosuo
Journal:  Ann Rheum Dis       Date:  1998-05       Impact factor: 19.103

10.  Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort.

Authors:  Jacques-Eric Gottenberg; Corinne Miceli-Richard; Béatrice Ducot; Philippe Goupille; Bernard Combe; Xavier Mariette
Journal:  Arthritis Res Ther       Date:  2009-07-23       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.